well ACUR did do a follow up study after they got a CRL last year to address the deterrence issue. however, i am not sure if it will be enough. but, Purdue Pharma got their version thru of Oxycodone with no label though and it had hoped for that precious label.
if there is a favorable view in those docs they post, i may consider picking up some.
News 
Market Data 
Discover 
